Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study

What Was Tested

This randomized controlled trial paper looks at Exenatide.

The 72 h fasting test, gold standard for diagnosing endogenous hyperinsulinemic hypoglycemia (EHH), is cumbersome and costly.

The researchers evaluated exenatide, a GLP-1 receptor agonist, as a faster, less burdensome alternative diagnostic tool.

Who Took Part

According to the abstract, 14 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Clinical monitoring and measurements of glucose, insulin, C-peptide, and proinsulin were performed for 4 h.

Follow-up for EHH patients included imaging and histology.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

In the crossover set-up each of the patients took both Exenatide and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Exenatide, Hypoglycemia, Hypoglycemic Agents, Blood Glucose, Hyperinsulinism, Proinsulin and Insulin.

Author keywords: endogenous hyperinsulinemic hypoglycemia, fasting test and insulinoma.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (European journal of endocrinology), a journal based in England.

More context: the Exenatide compound page, all human trials.